Role of MRI Assessment in Fertility Sparing Treatment for Cervical Cancer at Staging and Follow-up and for Identification of Risk Factors for Aggressive Disease.
The purpose of this study is to investigate the role of MRI, including DWI, in the staging and evaluation of response to fertility sparing treatment, including both primary surgery Protocol FeST-CC V.1.0 of November 10, 2023 Pag. 5 \| 23 (RT or CKC) or after NACT, followed by CKC, in patients with ECC (FIGO 2018 stage IB1- IIA1), desiring to preserve their fertility.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients with cervical cancer FIGO stage up to IB2-IIA1 (T size \< 4 cm) wishing to preserve fertility treated at the Oncological Gynecology Unit of Foundation Policlinico Universitario Agostino Gemelli.
* absence of nodal disease,
* no menopausal status
* wish to preserve fertility
* refusal of radical treatment.
* Patients who had a pre-treatment and post-treatment magnetic resonance imaging.
* Availability of digital MR images and histopathological samples.
Exclusion Criteria:
* Patients aged under 18 years.
* Neuroendocrine cervical tumours or other rare histology, such as glassy cells or clear cell carcinoma non-HPV related adenocarcinoma.
* ongoing pregnancy at the time of diagnosis.
* Patients without available MR images on digital media or with low quality images.
Primary outcome measure(s)
MRI accuracy in preoperative staging of early stage cervical cancer for fertility-sparing treatment — 3 years The primary objective is to investigate the role of MRI in preoperative staging of early stage cervical cancer, in patients eligible for fertility-sparing treatment (FIGO stage up to IB2-IIA1 with T size \< 4 cm).
Trial sites (1)
Facility
City
Region
Status
Advanced Radiology Center- Fondazione Policlinico Universitario A. Gemelli IRCCS
Rome
Italy
Recruiting
More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
